Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

NCT04183218 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT04183218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04183218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Completed
Start date
September 23, 2019
Completion date
May 2, 2024
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage 0 esophageal adenocarcinoma ajcc v8, clinical stage 0 esophageal squamous cell carcinoma ajcc v8, clinical stage i esophageal adenocarcinoma ajcc v8, clinical stage i esophageal squamous cell carcinoma ajcc v8, clinical stage ii esophageal adenocarcinoma ajcc v8, clinical stage ii esophageal squamous cell carcinoma ajcc v8, clinical stage iia esophageal adenocarcinoma ajcc v8, clinical stage iib esophageal adenocarcinoma ajcc v8, clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii esophageal squamous cell carcinoma ajcc v8, localized esophageal carcinoma, localized lung carcinoma, pathologic stage 0 esophageal adenocarcinoma ajcc v8, pathologic stage 0 esophageal squamous cell carcinoma ajcc v8, pathologic stage i esophageal adenocarcinoma ajcc v8, pathologic stage i esophageal squamous cell carcinoma ajcc v8, pathologic stage ia esophageal adenocarcinoma ajcc v8, pathologic stage ia esophageal squamous cell carcinoma ajcc v8, pathologic stage ib esophageal adenocarcinoma ajcc v8, pathologic stage ib esophageal squamous cell carcinoma ajcc v8, pathologic stage ic esophageal adenocarcinoma ajcc v8, pathologic stage ii esophageal adenocarcinoma ajcc v8, pathologic stage ii esophageal squamous cell carcinoma ajcc v8, pathologic stage iia esophageal adenocarcinoma ajcc v8, pathologic stage iia esophageal squamous cell carcinoma ajcc v8, pathologic stage iib esophageal adenocarcinoma ajcc v8, pathologic stage iib esophageal squamous cell carcinoma ajcc v8, pathologic stage iii esophageal adenocarcinoma ajcc v8, pathologic stage iii esophageal squamous cell carcinoma ajcc v8, pathologic stage iiia esophageal adenocarcinoma ajcc v8, pathologic stage iiia esophageal squamous cell carcinoma ajcc v8, pathologic stage iiib esophageal adenocarcinoma ajcc v8, pathologic stage iiib esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage i esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage i esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage ii esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage ii esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iii esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iiia esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iiib esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib esophageal squamous cell carcinoma ajcc v8, stage 0 lung cancer ajcc v8, stage i lung cancer ajcc v8, stage ia1 lung cancer ajcc v8, stage ia2 lung cancer ajcc v8, stage ia3 lung cancer ajcc v8, stage ib lung cancer ajcc v8, stage ii lung cancer ajcc v8, stage iia lung cancer ajcc v8, stage iib lung cancer ajcc v8, stage iii lung cancer ajcc v8, stage iiia lung cancer ajcc v8, stage iiib lung cancer ajcc v8, stage iiic lung cancer ajcc v8